Next Potential Big ADC Player? Korean Firms Take It Up A Notch
Most Assets Still Early Stage
Executive Summary
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.
You may also be interested in...
How Pinotbio Is Helping Build Korea's ADC Ecosystem
Pinotbio CEO Dooyoung Jung shares his views on the Korean ADC industry’s situation and efforts needed for the sector to grow, the strengths of his company's camptothecin-based platform and pipeline, and R&D and business strategies.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.